Navigation Links
Lexapro Loses First-Line Position for the Treatment of Major Depression
Date:5/12/2009

Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources

Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles

WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major depression. Lexapro may have lost its first-line dominance because of the increasing frequency of step therapy restrictions requiring patients to first try therapy with citalopram (Forest Laboratories' Celexa, generics) before being reimbursed for Lexapro.

The new report entitled Treatment Algorithms in Major Depression also finds that although atypical antipsychotics do not capture substantial patient share until the third-line of therapy in newly diagnosed patients, third-line patient share has grown from 11.8 percent to 17.1 percent since last year's report. This growth is likely attributed to physicians' growing comfort with these agents given the FDA approval of Bristol-Myers Squibb/Otsuka's Abilify as an adjunct therapy in 2007 and the expected upcoming FDA approval of AstraZeneca's Seroquel XR for treating this disease.

"AstraZeneca's Seroquel, Pfizer's Geodon and Eli Lilly's Zyprexa all capture more patient share in the third line in our current analysis versus the analysis in our 2008 report. Even though these agents are not FDA-approved for major depression, physicians appear to be becoming more comfortable with atypicals as a class, a trend that may reflect a spill-over effect from Abilify's approval," stated Michael Malecki, Ph.D., analyst at Decision Resources.

By pairing patient-level claims data with primary survey data, the report can be used to build patient-flow models and highlight assumptions driving these models.

"Of all patients in our claims database taking Wyeth's Pristiq for major depression, only 2.6 percent took the drug on the first line. Among patients moving to Pristiq from another drug, 13.0 percent had taken Wyeth's Effexor XR on the previous line of therapy, indicating that Pristiq is drawing business from more than just Effexor XR," said Dr. Malecki. "Surveyed physicians point to better reimbursement of and greater familiarity with Effexor XR as the top reasons they choose this drug. This suggests that efforts made by Wyeth to move patients from Effexor XR to Pristiq over the next couple of years will have to overcome these hurdles. Likewise, any forecast patient-flow between these drugs will also have to take into account Pristiq's limitations."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
2. Zoloft, Lexapro the Best of Newer Antidepressants
3. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
4. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. HEI, Inc. Closes on Sale of RFID Division Assets
7. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
8. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
9. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
10. MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor
11. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... 26, 2017 , ... Silver Birch of Hammond, a new assisted lifestyle community, ... four acres of land at 5620 Sohl Avenue in Hammond, serves older adults who ... 125 studio and one-bedroom apartments. Each of the private apartments at Silver Birch features ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing ... blog post on insurance options. If a Bay Area patient has to search for ... and money. Visiting an in-network provider for a second opinion can ensure a patient ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
(Date:5/3/2017)... 3, 2017 A Catheterization Laboratory is ... healthcare facility. Commonly referred to as cath lab, ... diagnostic imaging technology to give physicians visual access ... these spaces, a team of physicians perform life-saving ... coronary intervention, congenital heart defect closure, stenotic heart ...
(Date:5/3/2017)... , May 3, 2017  Getinge, a leading ... to quality enhancement and cost efficiency within healthcare ... study of contemporary practice demonstrating that intra-aortic balloon ... for critically ill patients. The single-center, retrospective, observational ... large volume MEGA ® 50cc intra-aortic balloon ...
Breaking Medicine Technology: